Factory selling Lateral Flow Test Antigen - EZER Flu&Covid-19 Antigen Duo rapid test – Genesis
Factory selling Lateral Flow Test Antigen - EZER Flu&Covid-19 Antigen Duo rapid test – Genesis Detail:
Introduction
Clinical signs and symptoms of respiratory viral infection due to SARS-CoV-2 and influenza can be similar. SARSCoV-2, influenza A and influenza B viral antigens are generally detectable in upper respiratory specimens during the acute phase of infection.
Influenza virus belongs to the family of Orthomyxoviridae, and immunologically diverse, single-stranded RNA viruses. There influenza A and B virus is the main pathogen that severe illnesses both in human and in many animal species. Based on the current epidemiological investigation, the incubation period is 1 to 4 days. The main manifestations include acute fever, general aching and respiratory symptoms. Both Type A and B viruses can circulate simultaneously, but usually one type is dominant during a given season.1
COVID-19 is an acute respiratory infectious disease. People are generally susceptible. Currently, the patients infected by the novel coronavirus are the main source of infection; asymptomatic infected people can also be an infectious source. Based on the current epidemiological investigation, the incubation period is 1 to 14 days, mostly 3 to 7 days. The main manifestations include fever, fatigue and dry cough. Nasal congestion, runny nose, sore throat, myalgia and diarrhea are found in a few cases.
EZERTM Flu & COVID-19 Antigen Duo Rapid Test is intended for the simultaneous qualitative detection and differentiation of the nucleocapsid protein antigens from SARS-CoV-2, influenza A and influenza B in direct nasopharyngeal (NP) specimens. The detection is based on the antibodies which were developed specifically recognizing and reacting with the nucleoprotein of virus.
Detection
EZERTM Flu & COVID-19 Antigen Duo Rapid Test is the simultaneous qualitative detection and differentiation of the nucleocapsid protein antigens from SARS-CoV-2, influenza A and influenza B in direct nasopharyngeal (NP) specimens.
Specimen
Nasopharyngeal
Limit of Detection (LoD)
2019 Novel Coronavirus: 74.8 TCID50/mL
Influenza A
| Influenza Viral Strain |
Calculated |
| A/New Caledonia/20/1999_H1N1 |
8.50×103 |
| A/California/04/2009_H1N1 |
2.11×103 |
| A/PR/8/34_H1N1 |
2.93×103 |
| A/Bean Goose/Hubei/chenhu XVI35-1/2016_H3N2 |
4.94×102 |
| A/Guizhou/54/89_H3N2 |
3.95×102 |
| A/Human/Hubei/3/2005_H3N2 |
2.93×104 |
| A/Bar-headed Goose/QH/BTY2/2015_H5N1 |
1.98×105 |
| A/Anhui/1/2013_H7N9 |
7.90×105 |
Influenza B.
| Influenza Viral Strain |
Calculated |
| B/Victoria |
4.25×103 |
| B/Yamagata |
1.58×102 |
Accuracy
Influenza A
Relative Sensitivity : 86.8%
Relative Specificity: 94%
Accuracy: 92.2%
Influenza B
Relative Sensitivity: 91.7%
Relative Specificity: 97.5%
Accuracy: 96.1%
COVID-19
Relative Sensitivity: 96.6%
Relative Specificity: 100%
Accuracy: 98.9%
Time to results
Read results at 15minutes and no more than 30 minutes.
Kit storage conditions
2~30°C.
Contents
| Test devices | 20 tests |
| Sterilized swabs | 20 pcs |
| Extraction tubes (with 0.5mL extraction | 20 pcs |
| buffer) | 20 pcs |
| Nozzle with filter | 1 pcs |
| Tube Stand | 1 pcs |
Ordering Information
|
Product |
Cat.No. |
Contents |
|
EZERTM Flu & COVID-19 Antigen Duo |
P211137 |
20 Tests |
Product detail pictures:
Related Product Guide:
We are proud of the high customer satisfaction and wide acceptance due to our persistent pursuit of high quality both on product and service for Factory selling Lateral Flow Test Antigen - EZER Flu&Covid-19 Antigen Duo rapid test – Genesis , The product will supply to all over the world, such as: Morocco, Malaysia, Ghana, If you need any of our products, or have other items to be produced, please send us your inquiries, samples or detailed drawings. Meanwhile, aiming to develop into an international enterprise group, we look forward to receiving offers for joint ventures and other cooperative projects.
By Eleanore from St. Petersburg - 2018.06.28 19:27
Managers are visionary, they have the idea of "mutual benefits, continuous improvement and innovation", we have a pleasant conversation and Cooperation.
By Elvira from Angola - 2018.06.19 10:42
